Publication | Closed Access

C3a and C5a receptor antagonists ameliorate endothelial-myofibroblast transition via the Wnt/β-catenin signaling pathway in diabetic kidney disease

Endothelial Cell PathobiologyUrologyMedicineVascular PharmacologyDiabetesImmunologyEndothelial DysfunctionDiabetic Kidney DiseaseVascular BiologyC5a Receptor AntagonistsDiabetes ComplicationsEndothelial-myofibroblast TransitionChronic Kidney DiseaseCell BiologyCell SignalingNephrologyKidney ResearchMolecular Signaling